logo

For the Inventor, By the Inventor

Kenilworth, NJ, United States of America

Schering Corporation


USPTO Granted Patents = 1,829

% Expired Patents = 24.1



Trademarks = 121

Forward Citations = 23,318

Loading Chart...
Loading Chart...

1,400 inventors (with patents filed for the assignee):

goldMedal Viyyoor Moopil Girijavallabhan (127 out of 130 patents)

silverMedal Ashit K Ganguly (104 out of 106 patents)

bronzeMedal Ronald J Doll (92 out of 105 patents)

4.  Neng-Yang Shih (82 out of 110 patents)

5.  F George Njoroge (71 out of 99 patents)

6.  Bernard R Neustadt (68 out of 77 patents)

7.  Anil K Saksena (59 out of 61 patents)

8.  Alan K Mallams (59 out of 61 patents)

9.  John J Piwinski (51 out of 72 patents)

10.  Samuel Chackalamannil (50 out of 77 patents)

11.  Joseph A Kozlowski (50 out of 104 patents)

12.  Timothy J Guzi (50 out of 65 patents)

13.  John W Clader (50 out of 59 patents)

14.  Stuart W McCombie (48 out of 48 patents)

15.  Brian Alexander McKittrick (47 out of 68 patents)


Core Competencies:
Monoclonal Antibodies
CX3C Chemokines
IL-23 Antibodies
Protease Inhibitors
Viral Infections
Immune Responses
Inflammatory Disorders
Tumor Growth
Pharmaceutical Formulations
Nucleic Acids
Therapeutic Combinations
Cancer Treatments

1,829 patents:

1. 8343492 - Method for blocking binding of CX3C chemokines using CX3C chemokine antibodies (2013-01-01),
2. 8293883 - Engineered anti-IL-23P19 antibodies (2012-10-23),
3. 8273790 - Exo-selective synthesis of himbacine analogs (2012-09-25),
4. 8263748 - Lyophilized formulations of engineered anti-IL-23p19 antibodies (2012-09-11),
5. 8263080 - Use of agonists and antagonists of IL-23 in the treatment of viral infection (2012-09-11),
6. 8263070 - Methods of modulating CD200 receptors (2012-09-11),
7. 8258319 - Exo- and diastereo- selective synthesis of himbacine analogs (2012-09-04),
8. 8257921 - NRIP1 regulation of apolipoprotein A1 (2012-09-04),
9. 8242112 - Heterocyclic aspartyl protease inhibitors (2012-08-14),
10. 8236309 - Use of bispecific antibodies to regulate immune responses (2012-08-07),
11. 8232372 - Engineered anti-TSLP antibody (2012-07-31),
12. 8227605 - 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors (2012-07-24),
13. 8226947 - Interleukin-10 antibodies (2012-07-24),
14. 8222259 - [object Object] (2012-07-17),
15. 8216571 - Fully human anti-VEGF antibodies and methods of using (2012-07-10),
Company Overview
Schering Corporation, headquartered in Kenilworth, NJ, specializes in the development and manufacturing of innovative therapies, particularly in the field of monoclonal antibodies. The company focuses on addressing complex medical challenges related to viral infections, inflammatory disorders, and tumor growth through advanced research in immune responses and specific therapeutic targets such as CX3C chemokines and IL-23 antibodies. Schering's commitment to scientific excellence positions it as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Schering Corporation USPTO Patent Assignee Logo
1,829 Patents

#1 in Kenilworth, NJ

#20 in New Jersey

#282 in US

#554 in the World

Kenilworth, NJ (US)
Kenilworth, NJ, United States of America

Schering Corporation

Forward Citations = 23,318

1,400 inventors:

goldMedal Viyyoor Moopil Girijavallabhan (127 out of 130 patents)

silverMedal Ashit K Ganguly (104 out of 106 patents)

bronzeMedal Ronald J Doll (92 out of 105 patents)

4.  Neng-Yang Shih (82 out of 110 patents)

5.  F George Njoroge (71 out of 99 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Schering Corporation. Retrieved from https://idiyas.com/company/schering

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…